Browsing Tag
GSK
35 posts
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
March 9, 2026
GSK bets on activin signalling with $950m 35Pharma acquisition
Discover why GSK plc is acquiring 35Pharma Inc. for $950 million and what HS235 could mean for the future of pulmonary hypertension treatment.
February 25, 2026
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
December 30, 2025
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
October 30, 2025
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
October 30, 2025
Positive CHMP opinion sets stage for GSK’s ready-to-use Shingrix syringe approval in Europe
GSK receives CHMP green light for Shingrix prefilled syringe. Learn how this vaccine format could simplify shingles protection across Europe.
October 22, 2025
GSK stock jumps as insider Luke Miels named next CEO — can he deliver growth before HIV patent cliff hits?
GSK shares rise after naming Luke Miels as CEO-designate to succeed Emma Walmsley on Jan 1, 2026. Find out what investors expect next.
September 29, 2025
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.
June 3, 2025
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
May 23, 2025
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies.
March 24, 2025